Ex­elix­is posts mixed re­sults for Cabome­tyx com­bo in ear­ly liv­er can­cer pa­tients, cast­ing doubt on piv­otal read­out

Ex­elix­is en­vi­sioned a first-line ap­proval for its su­per-sell­er Cabome­tyx in liv­er can­cer, but af­ter an in­ter­im read­out pro­duced mixed re­sults, that pic­ture is now a bit murky. De­spite fail­ing a key pri­ma­ry end­point, the com­pa­ny’s rac­ing full speed ahead to­ward a fi­nal read­out — and a po­ten­tial la­bel ex­pan­sion.

Cabome­tyx and Tecen­triq re­duced the risk of dis­ease pro­gres­sion or death in he­pa­to­cel­lu­lar car­ci­no­ma (HCC) pa­tients by 37% com­pared with so­rafenib (p= 0.0012), Ex­elix­is said Mon­day morn­ing. How­ev­er, it failed to achieve a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in over­all sur­vival at the in­ter­im analy­sis, and the com­pa­ny says the prob­a­bil­i­ty of hit­ting the end­point in time for the fi­nal analy­sis is low.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER